OncoMatch/Clinical Trials/NCT05223803
TERPS Trial for de Novo Oligometastic Prostate Cancer
Is NCT05223803 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Systemic Therapy for prostate cancer.
Treatment: Systemic Therapy — This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: to an overlapping site of a target lesion that would preclude further radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- Maryland Proton Treatment Center · Baltimore, Maryland
- UMMC · Baltimore, Maryland
- Upper Chesapeake Health · Bel Air, Maryland
- Central Maryland Radiation Oncology · Columbia, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify